Captor Therapeutics European Patent Application EP4347579A1 for MCL-1 Targeted Protein Degradation
Summary
Captor Therapeutics S.A. has obtained publication of European patent application EP4347579A1 covering bifunctional compounds designed to bind ubiquitin ligase and recruit the MCL-1 protein for degradation, with potential therapeutic application in oncology. The application was published on April 15, 2026 with claims spanning heterocyclic compound compositions under IPC classifications C07D 401/14, C07D 471/04, C07D 513/04, and related therapeutic uses under A61P 35/00 and A61K 31/4439. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The EPO Patent Bulletin published European patent application EP4347579A1 filed by Captor Therapeutics S.A. covering novel bifunctional degrader compounds that simultaneously bind an E3 ubiquitin ligase and the MCL-1 oncoprotein, marking a PROTAC-style therapeutic approach. The application claims priority to compounds falling under multiple IPC classifications including C07D 401/14, C07D 471/04, and C07D 513/04, with designated contracting states spanning the full EPC membership.
For pharmaceutical and biotech companies engaged in targeted protein degradation research, this publication represents potential prior art for competing MCL-1 degrader programs and may affect freedom-to-operate analyses for oncology drug development pipelines. Competitors should review their own compound structures against the claimed heterocyclic architectures and assess the therapeutic use claims directed at A61P 35/00 (neoplastic diseases).
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN
Publication EP4347579A1 Kind: A1 Apr 15, 2026
Applicants
Captor Therapeutics S.A.
Inventors
COTTENS, Sylvain, DREWNIAK-SWITALSKA, Magda, KACZANOWSKA, Katarzyna, TOMCZYK, Tomasz, TRACZ, Andrzej, WALCZAK, Michal, WOJCIK, Karolina
IPC Classifications
C07D 401/14 20060101AFI20221209BHEP C07D 401/04 20060101ALI20221209BHEP C07D 471/04 20060101ALI20221209BHEP C07D 513/04 20060101ALI20221209BHEP C07D 515/18 20060101ALI20221209BHEP A61P 35/00 20060101ALI20221209BHEP A61K 31/4439 20060101ALI20221209BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.